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Mast cells reside in tissues as terminally differentiated cells 
with a capacity to proliferate and migrate upon specific exter-
nal signals. Hematopoietic stem cell (HSC)–derived mast cell 
progenitors circulate in blood and populate all vascularized 
tissues, especially at sites exposed to the external environment, 
including skin, conjunctiva, upper airways, lungs, and intes-
tines (Voehringer, 2013). Mast cell differentiation, phenotype, 
function, and survival in these tissues are largely determined 
by their microenvironment, activating factors, and cytokine 
milieu (Galli et al., 2011).
A characteristic feature of mast cells is the presence of 
granules in their cytoplasm that contain a variety of biologi-
cally active molecules, including proteases (e.g., tryptase, chy-
mase); lysosomal enzymes (e.g., cathepsins); bioactive amines 
(e.g., histamine, serotonin); select cytokines (e.g., TNF, IL-15); 
and enzymes, including granzyme B, β-hexosaminidase, and 
β-glucuronidase (Wernersson and Pejler, 2014). Furthermore, 
heparin, a proteoglycan, is a vital component of mast cell 
granules that is essential for the packaging of histamine and 
mast cell proteases (Rönnberg et al., 2012).
Notably, several cell-surface receptors are involved 
in mast cell activation, including high-affinity IgE receptor 
FcεR1 and specific G protein–coupled receptors (GPCRs) 
such as endothelin receptor type A (ETA), complement com-
ponent 5a receptor (C5AR), adenosine A3 receptor (ADO 
RA3), and MAS-related GPR family member X2 (MRG 
PRX2). Mast cells also generate cytokines, chemokines, 
growth factors, and lipid mediators of inflammation (e.g., 
prostaglandins and leukotrienes; Abraham and St. John, 
2010). Therefore, equipped with a great capacity to respond 
to a variety of signals, mast cells have a unique and versatile 
role in the immune system.
Mast cells are implicated not only in allergic dis-
eases such as asthma, hay fever, and atopic dermatitis but 
also in nonallergic conditions including but not limited to 
stroke, myocardial infarction, and cystitis. Importantly, ther-
apeutic interventions to modulate mast cell functions can 
occur at several levels by blocking the action of released 
mediators or by preventing the transcription or release of 
mediators. Other targets include modulating mast cell mi-
gration, differentiation, survival, and intercellular interac-
tions. Hence, a thorough understanding of mast cell biology 
and heterogeneity along with their role in human health 
and disease is paramount.
This review will primarily focus on the molecular 
mechanisms of mast cell development, activation, and func-
tional diversity. In particular, we will highlight the recent 
findings in regard to the transcriptional program and signal 
transduction mechanisms that underlie the heterogeneity of 
mast cell functions. Furthermore, we will introduce the avail-
able mouse models, exploring their inherent advantages and 
disadvantages in investigating the biological questions in mast 
cell research. Finally, we will discuss the common human dis-
eases in which mast cells are implicated and highlight new 
therapeutic approaches currently envisaged to target mast cell 
functions in the clinical setting.
Mast cells are unique tissue-resident immune cells that express an array of receptors that can be activated by several extra-
cellular cues, including antigen–immunoglobulin E (IgE) complexes, bacteria, viruses, cytokines, hormones, peptides, and drugs. 
Mast cells constitute a small population in tissues, but their extraordinary ability to respond rapidly by releasing granule-stored 
and newly made mediators underpins their importance in health and disease. In this review, we document the biology of mast 
cells and introduce new concepts and opinions regarding their role in human diseases beyond IgE-mediated allergic responses 
and antiparasitic functions. We bring to light recent discoveries and developments in mast cell research, including regulation 
of mast cell functions, differentiation, survival, and novel mouse models. Finally, we highlight the current and future oppor-
tunities for therapeutic intervention of mast cell functions in inflammatory diseases.
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Heterogeneity and evolutionary adaptations of mast cells
In humans, mast cell subtypes are defined according to 
whether they are positive for chymase and tryptase (MCTC) 
or tryptase alone (MCT). MCTC cells are comparable with 
mouse connective tissue mast cells, and MCT cells are com-
parable with mouse mucosal mast cells. The MCTC subtype 
is predominantly found in skin, the gastrointestinal tract, and 
conjunctiva, whereas the MCT subtype is the predominant 
mast cell type in the lungs, nose, and sinuses. However, this 
traditional classification is simplistic, and mast cells show sig-
nificant plasticity (Galli et al., 2011). The microenvironment 
plays decisive roles in shaping mast cell development, phe-
notype, and function (Xing et al., 2011). Under basal condi-
tions, even within the same tissue, mast cell populations are 
phenotypically different and form further specific subpopu-
lations. In human lungs, for example, connective tissue mast 
cells in bronchi express higher levels of FcεR1 than alveolar 
and small-airway mast cells, suggesting location- and possibly 
function-dependent phenotypic alterations (Andersson et al., 
2009). This location-dependent phenotypic diversity has im-
portant implications in clinical manifestations of allergic dis-
eases. For instance, the MRG PRX2 receptor is expressed at 
high levels in MCTC cells in the skin but not in MCT cells in 
the lungs (Fujisawa et al., 2014). Therefore, activation of MRG 
PRX2 with diverse ligands, such as neuropeptide substance P, 
is associated with skin-specific effects such as itchiness.
Importantly, tissue-specific foreign microorganisms also 
contribute to the development and activation of mast cells, 
adding another layer of complexity to mast cell diversity. In 
mouse skin, for instance, skin microbiome can regulate the 
development of mast cells by inducing keratinocyte-derived 
stem cell factor (SCF) production, an essential growth factor 
for mast cell development (Wang et al., 2017). Also, in mouse 
skin, Staphylococcus aureus–derived δ toxin can induce mast 
cell activation and cause allergic skin disease (Nakamura et al., 
2013), suggesting the considerable impact of the microbiome 
on mast cell functions.
Adipose tissue is another location where mast cells re-
side in the body. It is well known that mast cell progenitors 
are released from the bone marrow and contribute to periph-
eral mast cell populations. However, it is now evident that ad-
ipose tissue is also a rich source of several hematopoietic cell 
types, including mast cells and mast cell progenitors (Poglio 
et al., 2010). Notably, the numbers of adipose tissue mast cells 
increase upon high-fat diet (HFD)–induced obesity in mice 
(Cildir et al., 2013). Although mast cells were recently found 
to be dispensable in regulating metabolic parameters such as 
fat mass and insulin sensitivity in mice (Gutierrez et al., 2015; 
Chmelař et al., 2016), the precise functions of adipose tissue–
resident mast cells have not yet been determined.
Mast cells perform diverse functions in health and dis-
ease. Their role in mounting an effective antiparasitic de-
fense is well established (Hepworth et al., 2012; Mukai et al., 
2017). For instance, in a recent study, intestinal mast cells in 
mice were shown to be crucial for the expulsion of intesti-
nal helminth Heligmosomoides polygyrus (Shimokawa et al., 
2017). In response to the invasion by helminth larvae, ATP 
is released from apoptotic intestinal epithelial cells. This acti-
vates mast cells to produce IL-33, which is important for the 
activation and IL-13 production of type 2 innate lymphoid 
cells (ILC2s), a process critical for the expulsion of helminths 
(Shimokawa et al., 2017). Furthermore, mast cells enhance in-
nate and adaptive host resistance to the toxicity and mortality 
induced by arthropod and reptile venoms (Galli et al., 2016). 
In particular, mast cell–derived carboxypeptidase A3 (CPA3) 
and mast cell protease 4 (MCPT4) were found to inactivate 
toxins Sarafotoxin 6B and Helodermin, respectively (Fig. 1). 
Recently, mast cells were also shown to be beneficial for pre-
serving cardiac function after myocardial infarction in mice 
(Ngkelo et al., 2016). In response to a myocardial infarction, 
mast cell progenitors from white adipose tissue were recruited 
to the heart and differentiated into mature mast cells. Mast 
cell–derived tryptase mediated muscle contractility and pre-
served heart function after myocardial infarction. In line with 
this, mast cell depletion was associated with decreased cardiac 
function after myocardial infarction (Ngkelo et al., 2016). An-
other beneficial role of mast cells has been identified in cys-
titis, where mouse mast cells help to eradicate uropathogenic 
Escherichia coli (UPEC)–infected bladder epithelial cells 
(BECs). After infection, BECs release IL-1β and recruit mast 
cells, and in turn mast cell–derived chymase is endocytosed 
by BECs, which induce their cytolytic death (Choi et al., 
2016). It is also well known that mast cells are integral to the 
pathophysiology of anaphylaxis. For example, mucosal mast 
cells in mouse intestine contribute to food-induced intestinal 
anaphylaxis by being a major source of IL-9 (Chen et al., 
2015). Accordingly, mice ablated for IL-9–producing muco-
sal mast cells had decreased food allergies. Similarly, mouse 
meningeal mast cells can worsen stroke pathology by releas-
ing IL-6 and chemokine (C-C motif) ligand 7 (CCL7) and 
promoting the infiltration of granulocytes, brain swelling, and 
infarct size (Arac et al., 2014).
Although there are many examples of the heterogeneity 
of mast cells, in many cases the mechanistic details of this di-
versity remain underexamined. To gain a better understanding 
of the molecular mechanisms of mast cell heterogeneity and 
functional plasticity, it is essential to uncover the transcrip-
tional program for mast cell development and activation.
Mast cell transcriptional program
To understand the transcriptional heterogeneity of tis-
sue-resident mast cells, basal transcriptomes of mouse mast 
cells from different tissues (peritoneum, skin, esophagus, tra-
chea, and tongue) were analyzed as part of the Immunological 
Genome Project (ImmGen; Dwyer et al., 2016). These results 
indicated that mast cells are very distantly related to the other 
hematopoietic cell types (Dwyer et al., 2016). Interestingly, 
basophils, which are widely considered to have similar func-
tions to mast cells, exhibit a vastly different transcriptome. 
ImmGen results also pointed out important and surprising 
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transcriptional differences among different tissue-resident 
mast cells. Notably, peritoneal and skin mast cells have the 
greatest transcriptional diversity. For example, the cell-surface 
glycoprotein CD34, an adhesion molecule previously consid-
ered to be a mast cell marker, was expressed in all mast cell 
types except skin mast cells. However, CD59a, a complement 
system regulator, had the highest expression in skin mast cells 
but had no expression in peritoneal mast cells in mice.
In primary human mast cells, however, transcriptomic 
data are more limited. As part of the Functional Annota-
tion of the Mammalian Genome (FAN TOM) project, the 
transcriptomes of human skin–derived mast cells have been 
analyzed using cap analysis of gene expression (CAGE) se-
quencing (Motakis et al., 2014). Similar to mouse mast cells, 
human skin–derived mast cells were also found to be distantly 
related to other immune cell types in humans. FAN TOM 
analysis also discovered novel regulators of human mast cell 
functions, including bone morphogenetic protein receptor 
type 1A (BMPR1A). Importantly, stimulation of human mast 
cells with bone morphogenetic protein receptor (BMPR) li-
gand BMP4 prolonged mast cell survival and increased the 
histamine release upon FcεR1 cross-linking (Motakis et al., 
2014), suggesting a cross talk between BMPRs and FcεR1 
signaling in the human skin microenvironment. Overall, these 
results in mouse and human mast cells strongly reinforce the 
well-known concept of heterogeneity of mast cells in differ-
ent tissues and species.
The core elements of the transcriptional program es-
sential for mast cell development and maintenance in tissues 
encompass several transcription factors (TFs). These include 
microphthalmia-associated transcription factor (MITF), 
GATA binding protein 2 (GATA-2), and STAT-5, which are 
essential for orchestrating mast cell responses at steady state 
(Qi et al., 2013; Li et al., 2015). Several effector mast cell pro-
teases and cell-surface receptors responsible for mast cell acti-
vation are transcribed by the coordinated actions of these TFs 
(Tshori and Nechushtan, 2012). MITF is a well-known TF in 
the melanocytic lineage (Levy et al., 2006), but it is also rec-
ognized as a key TF for mast cell development (Morii et al., 
2004). MITF controls the expression of a diverse set of genes, 
including Mcpt4 and SCF receptor (Kit), which are import-
ant for mast cell functions (Shahlaee et al., 2007). Mast cells 
and basophils show various phenotypic similarities despite 
their different anatomical locations; basophils are found in 
circulating blood, whereas mast cells are tissue resident. Using 
pre-basophil and mast cell progenitors (preBMPs), CCA AT/
enhancer-binding protein α (C/EBPα) has been found to be 
critical for basophil fate specification, whereas MITF is cru-
cial for mast cell specification in mice (Qi et al., 2013). Nota-
bly, MITF and C/EBPα have been shown to antagonize each 
other’s transcriptional programs, and the expression of both 
C/EBPα and MITF is STAT-5 dependent (Qi et al., 2013). 
STAT-5 was previously shown to be important for mast cell 
survival in mice (Shelburne et al., 2003). In addition, STAT-5 
Figure 1. Evolutionary adaptations of mast 
cell functions. Mast cell–derived mediators are 
critically involved in the detoxification of arthro-
pod and reptile venoms. For example, whereas 
CPA3 is involved in the inhibition of Sarafotoxin 
6B, MCPT4 is critical for the inhibition of Helo-
dermin. Mast cells also contribute to the Th2-type 
immune response, which is critical for the preven-
tion of helminth infections.
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in mast cells is required for skin inflammation, and mast cell–
specific deletion of STAT-5 ameliorated atopic dermatitis in 
mice (Ando et al., 2014). GATA-2 is another critical factor 
for mast cell identity and function. GATA-2 was found to be 
vital for differentiation of preBMPs into basophils and mast 
cells in mice (Li et al., 2015). Notably, a large number of genes 
important for mast cell functions, including Fcer1a, Kit, and 
histidine decarboxylase (Hdc) are dysregulated in the absence 
of GATA-2. Similar to MITF, GATA-2 levels were also pro-
posed to be regulated by STAT-5 in mast cells (Li et al., 2015), 
and forced expression of GATA-2 was sufficient to drive ba-
sophil and mast cell differentiation in mice. In another study 
in which the GATA-2 DNA-binding domain (GATA2ΔCF) 
was deleted in mice, BM-derived mast cell (BMMC) numbers 
were greatly reduced (Ohmori et al., 2015), confirming the 
important role of GATA-2 DNA binding and trans-activation 
for mast cell identity. Recently, using single-cell transcrip-
tomic analysis of pre-granulocyte–macrophage progenitors 
(preGMs), GATA-1, another member of the GATA family 
of TFs, was also shown to be critical for marking progeni-
tor cells generating mast cells, eosinophils, megakaryocytes, 
and erythroids in mice (Drissen et al., 2016). However, using 
tamoxifen-inducible Gata1 knockout mice (Gata1−/y), an-
other study proposed that GATA-1, unlike GATA-2, is not 
essential for mast cell development in mice (Ohneda et al., 
2014). Using novel mast cell–specific genetic strategies might 
allow us to understand the precise contribution of GATA-1 
to mast cell homeostasis in future studies. Activating tran-
scription factor 3 (ATF-3) is another TF that has been shown 
to influence mast cell development in mice (Gilchrist et al., 
2010). ATF-3–deficient mast cells have significant develop-
mental defects in mouse peritoneum and skin. Also, BMMCs 
from ATF-3–deficient mice have impaired degranulation but 
elevated IL-4 and IL-6 levels upon activation. However, the 
precise role of ATF3 in mast cell survival is not clear.
In addition to transcriptional activators, transcrip-
tional repressors may also play an important role in mast 
cells. For example, hairy and enhancer of split 1 (HES1) 
is a repressive TF highly expressed in mast cells. HES1 is a 
Notch-responsive factor, and HES1 overexpression in mast 
cell precursors results in down-regulation of C/EBPα, a 
process important for mouse mast cell lineage commitment 
(Sakata-Yanagimoto et al., 2008). However, the precise re-
pressive function of HES1 in mast cells is unclear and re-
quires further investigation. In macrophages, HES1 has been 
described as a negative regulator of inflammation by limiting 
the levels of chemokine (C-X-C motif) ligand 1 (CXCL1; 
Shang et al., 2016), and it remains to be determined whether 
such regulatory mechanisms also exist in mast cells. Finally, 
for cell type specification, differential DNA-binding sites of 
TFs are crucial to drive the cell type–specific transcriptional 
program. It has been reported that the same TFs with sim-
ilar abundance show differential binding patterns in mouse 
BMMCs and hematopoietic precursor cells (Calero-Nieto 
et al., 2014). There is also cooperativity among the TFs to 
drive an efficient gene expression program. The Mcpt4 
locus, for example, is bound by many TFs such as GATA-
2, MITF, and c-FOS cooperatively mediating its transcrip-
tion (Calero-Nieto et al., 2014). Therefore, TF cooperativity 
seems to be a critical factor for lineage commitment and 
basal expression of key genes in mast cells.
Although transcriptional analysis of mast cell devel-
opment and activation is emerging, the epigenetic regula-
tion of these processes is not well understood. In particular, 
how mast cell chromatin regulates mast cell functions is 
unclear. Recently, to address some of these questions, the 
functions of certain chromatin regulatory enzymes have 
been studied in mast cells (Fig. 2). For instance, tet meth-
ylcytosine dioxygenase 2 (TET2) is a methyl cytosine di-
oxygenase enzyme that converts 5-methylcytosine (5-mC) 
to 5-hydroxymethylcytosine (5-hmC) and thereby medi-
ates demethylation of DNA (Rasmussen and Helin, 2016). 
Recently, TET2 was shown to be important for mediating 
mouse mast cell proliferation and in vitro differentiation 
(Montagner et al., 2016). Interestingly, both enzymatic ac-
tivity–dependent and independent functions of TET2 have 
been uncovered in mast cells. Although BMMCs from 
TET2-deficient mice have differential 5-hmC and tran-
scriptional profiles depending on their deoxygenase ac-
tivity, increased proliferation observed in TET2-deficient 
mast cells was independent of its enzymatic activity, sug-
gesting other as-yet-unknown functions of TET2 in mast 
cells. Another epigenetic regulator, DNA methyltransferase 
3a (DNMT3a), has also been suggested to control mast cell 
functions (Leoni et al., 2017). As opposed to TET2, DNMT3a 
is a DNA methyltransferase adding methyl groups to CpG 
elements in DNA (Denis et al., 2011). Notably, BMMCs from 
DNMT3a-deficient mice are hyperresponsive to FcεR1 
cross-linking, with increased degranulation and cytokine 
production (Leoni et al., 2017). Similarly, when recon-
stituted in mast cell–deficient mouse models, DNMT3a- 
deficient mast cells showed significantly elevated passive 
cutaneous anaphylaxis (PCA) responses. It is proposed that 
these effects, at least in part, might be due to a decrease in 
the levels of IQ motif-containing GTPase-activating pro-
tein 2 (IQG AP2), which regulates cytoskeleton dynamics 
in mast cells (Leoni et al., 2017). Another interesting epi-
genetic mechanism operating in mast cells is mediated by 
mast cell protease tryptase. Although mast cell proteases are 
primarily located to cytoplasmic granules, tryptase is also 
observed in the nucleus (Melo et al., 2014). Importantly, 
tryptase has been shown to catalyze the clipping of his-
tone H2 and H3 in chromatin. In line with this, BMMCs 
from tryptase-deficient mice accumulate lysine 5–acetyl-
ated H2B (H2BK5ac), which also leads to induction of 
non–mast cell lineage genes (Melo et al., 2017). Further 
studies seeking to define the key mechanisms in the mast 
cell transcriptional program will open up opportuni-
ties in an area of potentially highly specific and effective 
therapeutic interventions.
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Transcriptional regulation in activated mast cells
Several TFs are known to orchestrate the transcriptional re-
sponse in activated mast cells for de novo synthesis of cy-
tokines and chemokines. Similar to their roles in other cell 
types, NFAT, activator protein 1 (AP-1), and NF-κB have 
well-studied roles in driving transcription of inflammatory 
genes in activated mast cells (Marquardt and Walker, 2000; 
Lee et al., 2004; Klein et al., 2006). In addition, NF-κB sig-
naling components have been implicated in mast cell de-
granulation. As an indispensable part of the NF-κB signaling 
pathway, IκB kinase 2 (IKK2) is an upstream kinase phos-
phorylating IκBα and priming its degradation to activate 
NF-κB subunits for DNA binding and trans-activation (Shin 
et al., 2014; Tong and Tergaonkar, 2014; Cildir et al., 2016). 
Importantly, IKK1 and IKK2 also have other cellular sub-
strates independent of their roles in NF-κB signaling (Oeck-
inghaus et al., 2011). In the context of mast cell functions, 
it has been suggested that IKK2 is critical for phosphory-
lation of synaptosomal-associated protein 23 (SNAP23), an 
important regulator of mast cell degranulation (Lorentz et al., 
2012). Because IKK2 deficiency results in embryonic lethal-
ity in mice, IKK2-deficient mouse fetal liver–derived mast 
cells have been generated and shown to have impaired de-
granulation upon FcεR1 cross-linking (Suzuki and Verma, 
2008). However, in a subsequent study, connective tissue mast 
cell–specific deletion of IKK2 (Mcpt5-Cre, IKK2F/F mice) 
resulted in normal degranulation but impaired cytokine pro-
duction from peritoneal-derived mast cells (Peschke et al., 
2014). In the same study, Mcpt5-Cre–mediated deletion of 
NF-κB essential modulator (NEMO; another essential sub-
unit of the IKK complex mediating NF-κB activation) also 
resulted in impaired cytokine production from activated 
mouse peritoneal mast cells. Finally, using BMS-345541, a 
pharmacological inhibitor of IKK2 kinase activity, a recent 
study proposed that IKK2 is important for SNAP23 and syn-
taxin-4 (STX4) complex formation and cytokine production 
upon FcεR1 cross-linking (Gaudenzio et al., 2016). Overall, 
it is possible that the role of IKK2 in mast cell degranulation 
is context dependent, but IKK2 is undeniably essential for the 
synthesis of a subset of cytokines in activated mast cells by 
controlling NF-κB activation.
Early growth response 1 (EGR1) and EGR2 are early- 
response TFs that are members of the zinc finger TF family 
and are induced by a diverse array of extracellular stimuli in 
different cell types (Seiler et al., 2012). In mouse BMMCs, 
de novo synthesized EGR1 has been shown to regulate 
TNF and IL-13 production upon FcεR1 cross-linking (Li 
et al., 2006, 2007). A similar TF, EGR2, however, has been 
shown to regulate chemokine (C-C motif) ligand 1 (CCL1) 
production in mouse fetal liver–derived mast cells, which is 
important for the recruitment of T cells into inflamed tis-
sues (Wu et al., 2013). Although the binding of EGR1 and 
EGR2 has been suggested to occur in the promoter regions 
of certain proinflammatory genes, it is, however, import-
ant to identify the genome-wide binding patterns of EGR1 
and EGR2 to obtain a complete picture of their effect on 
Figure 2. Epigenetic control of mast cell ho-
meostasis. DNA methyltransferase DNMT3a is in-
volved in de novo DNA methylation in CpG regions, 
which is important for gene expression regulation 
and homeostasis in mast cells. DNMT3a-deficient 
mouse mast cells are hyper-responsive to FcεR1 
cross-linking and release increased mediators 
and cytokines. TET2, however, converts 5-mC to 
5-hmC in DNA. TET2 functions are also important 
for mast cell proliferation and mediator release. 
TET2-deficient mouse mast cells are impaired in 
differentiation, but they have elevated prolifer-
ative capacity in culture. Importantly, TET2 me-
diates both enzymatic activity–dependent and 
independent functions in mast cells. Mast cell 
protease tryptase is another epigenetic regulator 
in mast cells. Nuclear tryptase is involved in the 
clipping of histone H2 and H3. Notably, tryptase 
deficiency results in increased H2BK5ac levels 
in non–mast cell genes.
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activated mast cells. Zinc finger E-box–binding homeo-
box 2 (ZEB2) is another zinc finger TF that is implicated 
in the activation of BMMCs based on siRNA-mediated 
knockdown experiments. Although it has been shown that 
ZEB2 is highly expressed in mast cells and knocking down 
ZEB2 levels caused impaired activation of mast cells upon 
FcεR1 cross-linking (Barbu et al., 2012), its genome-wide 
DNA-binding pattern in mast cells and genetic deficiency 
in mice require further investigation.
In conclusion, our understanding of the transcriptional 
dynamics of mast cell development and activation is limited, 
and most studies are still based on mouse mast cells. Because 
TFs are critical for the expression of cell-surface receptors 
and extracellular mediators involved in mast cell activation, 
strategies specifically targeting mast cell TFs could be devel-
oped and tested in future clinical studies.
Modes of mast cell activation
Although it is well known that mast cells can be activated 
by different ligand–receptor complexes, it has only recently 
become evident that there are notable differences between 
different modes of mast cell activation. The recent identi-
fication of the MRG PRX2 receptor and its mouse ortho-
logue Mrgprb2, which are activated by several ligands such 
as neuropeptide substance P, and several pseudoallergic drugs 
has opened up a new research avenue and introduced a new 
therapeutic target for the control of pseudoallergic reactions 
(McNeil et al., 2015). It has been shown that Mrgprb2 is spe-
cifically expressed on connective tissue mast cells but not on 
mucosal mast cells in mice, and the activation of Mrgprb2 and 
MRG PRX2 by diverse ligands leads to mast cell degranula-
tion (McNeil et al., 2015).
A disease relevance for MRG PRX2 has also started to 
emerge; the levels of MRG PRX2 expression on skin mast 
cells have been observed to be higher in chronic urticaria 
patients compared with healthy individuals (Fujisawa et al., 
2014), suggesting dynamic regulation of its surface expres-
sion on mast cells. Recently, an elegant study using large 
chemical libraries and structural modeling discovered novel 
agonists of MRG PRX2 (Lansu et al., 2017). These agonists 
include many opioid compounds and peptides such as (–) 
and (+) morphine; hydrocodone; sinomenine; dynorphin 
A; dynorphin B; and a synthetic compound, ZINC-3573, 
which has very high specificity toward MRG PRX2 but 
not to other GPCRs. Importantly, these compounds caused 
mast cell degranulation in human mast cells in an MRG 
PRX2-dependent manner (Lansu et al., 2017). Overall, these 
findings have important implications for humans; morphine 
and similar analgesics are known to induce histamine release 
and itching in humans (Baldo and Pham, 2012). However, 
whether the effects of opioid ligands on mast cells are also 
physiologically relevant should be tested in vivo using nonhu-
man primate models. MRG PRX2 and its mouse orthologue 
Mrgprb2 have only a 52% sequence homology, and MRG 
PRX2 is conserved only in primates. In line with this, opioid 
compounds did not show a significant effect on the Mrgprb2 
receptor (Lansu et al., 2017).
It has now become evident that there are important 
differences between MRG PRX2- and FcεR1-mediated 
mast cell activation and degranulation (Fig.  3). Classically, 
IgE-dependent mast cell activation occurs via FcεR1 com-
prising four polypeptide chains: an α, a β, and two γ (Galli 
and Tsai, 2012). The β and γ chains have an immunorecep-
tor tyrosine-based activation motif (ITAM) that is essential 
for signal transduction mediated by Lck/Yes novel tyrosine 
kinase (Lyn) and spleen tyrosine kinase (Syk) phosphoryla-
tions, whereas the extracellular domains of the α subunit bind 
to IgE (Blank et al., 2014). Immediately after antigen- and 
IgE-induced cross-linking of cell-surface FcεR1, activation 
of the kinases Lyn and Syk leads to the rapid phosphorylation 
of FcεR1 ITAMs and the subsequent activation of multiple 
downstream events, including increased cytosolic calcium lev-
els and cytoskeleton rearrangements such as microtubule po-
lymerization and actin depolymerization (Dráber et al., 2012; 
Fig.  3). Importantly, FcεR1-mediated mast cell activation 
involves a robust inflammatory response with newly made 
cytokines and chemokines, mediated by several TFs such as 
NFAT, AP-1, NF-κB, EGR1, and EGR2, and this response has 
been shown to be limited in MRG PRX2-mediated activa-
tion (Gaudenzio et al., 2016). Although FcεR1 cross-linking 
results in granule–granule fusions in cytoplasm before granule 
release, MRG PRX2 activation results in more uniform and 
rapid release of individual granules (Gaudenzio et al., 2016). 
Furthermore, FcεR1-mediated granule release is known to 
be orchestrated by several soluble N-ethylmaleimide–sensi-
tive factor-activating protein receptor (SNA RE) complexes 
and adaptor proteins, including but not limited to SNAP23, 
STX4, vesicle-associated membrane protein 8 (VAMP8), pro-
tein Unc-13 homologue D (MUNC 13-4), and Ras-related 
protein Rab-27B (RAB27B; Lorentz et al., 2012; Fig. 3), but 
the identity of these complexes is less well known in MRG 
PRX2-mediated degranulation. Finally, depending on the 
affinity of the antigen to IgE, FcεR1 cross-linking causes 
differential cellular and physiological effects in mast cells. Im-
portantly, the strength of, and qualitative changes in, the mo-
lecular signals downstream of FcεR1 can be discriminated by 
high-affinity or low-affinity antigen stimulus despite equiv-
alent FcεR1 phosphorylation (Suzuki et al., 2014). In par-
ticular, low-affinity antigens activate feline Gardner–Rasheed 
sarcoma viral oncogene homologue (Fgr) kinase and shift the 
balance from linker for activation of T cells (LAT1) adap-
tor molecules toward LAT2 adaptor molecules, which then 
initiates a more chemokine-based inflammatory response 
compared with the high-affinity antigens (Suzuki et al., 2014; 
Fig. 3). Consistent with the higher intracellular calcium in-
crease after FcεR1 cross-linking, high-affinity antigen bind-
ing also results in higher degranulation (Suzuki et al., 2014).
IgE binding to the FcεR1 complex is a major mech-
anism for activation of mast cells. However, it is uncertain 
how tissue-resident mast cells acquire IgE molecules from 
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Figure 3. Different modes of mast cell activation. Mast cell identity is maintained by the coordinated actions of several TFs such as MITF, GATA-2, 
STAT-5, and ATF-3. Mast cells can be activated by different GPCRs such as MRG PRX2 and high-affinity IgE receptor FcεR1. However, there are notable 
differences between MRG PRX2- and FcεR1-mediated mast cell activation. Although ligand binding to MRG PRX2 leads to intracellular calcium increase 
and degranulation, there is very limited cytokine response. However, high-affinity antigen-mediated FcεR1 cross-linking involves higher intracellular cal-
cium levels, degranulation, and inflammatory cytokine and chemokine response involving various TFs such as NF-κB, NFAT, AP-1, EGR1, and EGR2. Despite 
similar levels of FcεR1 receptor phosphorylation, low-affinity antigen-mediated FcεR1 cross-linking involves a smaller increase in intracellular calcium 
levels and degranulation, and the inflammatory response is more chemokine based compared with high-affinity antigen-mediated activation. This is due 
to the involvement of cytoplasmic Fgr kinase and the membrane-bound LAT2 adaptor. Finally, although cytoskeleton rearrangements such as microtubule 
polymerization and actin depolymerization are a common feature of all forms of degranulation, the components of SNA RE machinery are less well known 
in MRG PRX2-mediated degranulation.
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the bloodstream. By studying reporter IgE molecules, it has 
been demonstrated that tissue-resident perivascular mast 
cells acquire IgE by extending their protrusions across the 
blood vessel walls (Cheng et al., 2013). This indicates that 
IgE uptake is a dynamic process and that perivascular posi-
tioning of mast cells is important to sample IgE molecules in 
blood (Cheng et al., 2013).
It is important to note that coactivation of various 
cell-surface receptors can enhance or diminish FcεR1 sig-
naling in mast cells. For example, T cell immunoglobulin and 
mucin-domain containing-3 (TIM3) is a cell-surface im-
mune checkpoint regulator that is also expressed on mast cells 
(Phong et al., 2015). Importantly, cross-linking of the TIM3 
receptor with specific antibodies simultaneously with FcεR1 
cross-linking resulted in increased mast cell degranulation and 
cytokine secretion (Phong et al., 2015). Similarly, BMMCs 
from TIM3-deficient mice have been reported to have re-
duced activation-induced cytokine levels, suggesting positive 
regulatory functions of TIM3 in FcεR1 signaling (Phong et 
al., 2015). Sphingosine-1-phosphate receptor 2 (S1PR2) has 
also been proposed to regulate FcεR1 signaling, and S1PR2 
antagonists significantly reduce mast cell degranulation and 
cytokine secretion upon FcεR1 cross-linking (Oskeritzian 
et al., 2010). In addition, TNF receptor superfamily mem-
ber 14 (TNF RSF14) activation by its ligand cytokine TNF 
SF14 (LIG HT) has been reported to enhance FcεR1 signal-
ing and result in enhanced degranulation in both human mast 
cells and mouse BMMCs (Sibilano et al., 2016). By binding 
to IL-6R, IL-6 increases the reactivity of human mast cells 
to FcεR1 cross-linking by regulating the levels of STAT-3 
and suppressor of cytokine signaling 3 (SOCS3; Desai et al., 
2016). Similarly, by binding to IL33R/ST2, IL-33 pretreat-
ment increases the IgE-mediated degranulation and cytokine 
secretion in human mast cells (Joulia et al., 2017). In contrast, 
co-ligation of the allergy-inhibitory receptor (Allergin-1), an 
Ig-like receptor, and FcεR1 impairs degranulation in mouse 
BMMCs (Hitomi et al., 2010). A novel mechanism of inhi-
bition of mast cell responses was recently proposed. Referred 
to as trans-inhibition, it is mediated by phosphatidylinosi-
tol-3,4,5-trisphosphate 5-phosphatase 1 (SHIP1; Malbec et 
al., 2016). It was previously known that inhibitory receptor 
FcγRIIB blocks mast cell activation when it is co-engaged 
with FcεR1 (cis-inhibition). However, in trans-inhibition, 
it is proposed that receptors recruiting sufficient amounts 
of SHIP1 phosphatase, including but not limited to Fcγ-
RIIB, can inhibit FcεR1-mediated mast cell activation and 
Kit-dependent mast cell proliferation (Malbec et al., 2016). 
Overall, it is conceivable that in future studies other recep-
tors that regulate FcεR1- and MRG PRX2-dependent mast 
cell activation could be identified and targeted to allevi-
ate allergic inflammation.
New mouse models of mast cells
In vivo animal models have greatly enhanced our understand-
ing of mast cell functions. Many novel mouse models with 
different genetic strategies have recently been developed and 
used to test the previously proposed functions of mast cells 
and gain novel mechanistic insights. The functions of mast 
cells and mast cell–derived mediators have historically been 
analyzed using mouse models in which cell surface receptor 
KIT has been disrupted. Initially, these included mouse mod-
els WBB6F1-KitW/W-v and C57BL/6-KitW-sh/W-sh. These mod-
els use either point mutations, causing the Kit protein to be 
unable to be expressed on the cell surface (Kitw) and limiting 
its kinase activity (KitW-v), or an inversion mutation (KitW-sh) in 
upstream regulatory regions of the Kit locus in mice (Reber 
et al., 2012). Notably, both of these KIT-dependent mouse 
models use adoptive transfer of BMMCs into tissues, and 
there are concerns as to how closely adoptively transferred 
mast cells resemble native populations in tissues. Moreover, 
the route of BMMC injection, the number of injected cells, 
and the analysis time after the injection could also contribute 
to the variations in mast cell responses in these models. In ad-
dition, it is now evident that these models affect non–mast cell 
populations as well, thereby introducing inherent confound-
ing variables in mast cell research. For example, WBB6F1- 
KitW/W-v mice are anemic and sterile. They also have several 
abnormalities reported in other cell types, including decreased 
numbers of basophils and neutrophils, defects in interstitial 
cells of Cajal, melanocytes, and γδ T cells in the gut (Reber 
et al., 2012). However, whereas C57BL/6-KitW-sh/W-sh mice 
are fertile and not anemic, they show defects in melanocytes, 
reduced levels of IgE, and elevated numbers of neutrophils 
and basophils (Reber et al., 2012).
To circumvent some of the aforementioned problems 
in WBB6F1-KitW/W-v and C57BL/6-KitW-sh/W-sh mouse mod-
els, new KIT-independent mouse models have been gener-
ated to study mast cell functions. These new mouse models 
could lead to constitutive or inducible mast cell deficiency 
or allow mast cell–specific inactivation of genes of interest. 
Importantly, some findings on the roles of mast cells using 
KIT-dependent mouse models have been refuted using 
KIT-independent mouse models (Feyerabend et al., 2011; 
Gutierrez et al., 2015).
KIT-independent mouse models with constitutive 
mast cell deficiency include Mcpt5-Cre; R-DTA mice (in 
which the diphtheria toxin [DT] α chain is expressed in 
Mcpt5-expressing mast cells), Cpa3Cre/+ mice (also known 
as “Cre-Master,” heterozygous mice in which Cre is ex-
pressed under the Cpa3 promoter), and Cpa3-Cre; Mcl-1F/F 
mice (also known as “Hello Kitty” mice in which the an-
tiapoptotic gene Mcl-1 is deleted in Cpa3-expressing mast 
cells). Furthermore, mouse models with inducible depletion 
of mast cells include Mcpt5-Cre; iDTR mice (in which 
Mcpt5-Cre mice crossed with iDTRF/F mice, thereby allow-
ing Cre-dependent expression of DTR in Mcpt5-expressing 
mast cells and depletion of these cells upon DT injection), 
Mas-TRE CK mice (in which human DTR is expressed 
under the control of IL-4 intronic enhancer elements), and 
RMB mice (in which DTR and bright red td-Tomato [tdT] 
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fluorescent proteins are expressed in 3′ UTR of the mem-
brane spanning 4-domains A2 [MS4A2] gene encoding for 
the FcεR β chain; Reber et al., 2012; Dahdah et al., 2014). In 
addition, mast cell–specific gene deletion has been achieved 
with Mcpt5-Cre, Cpa3-Cre, and FcεR1β-Cre mouse mod-
els (Furumoto et al., 2011; Lilla et al., 2011; Peschke et al., 
2014). However, some of these new mouse models also have 
specific disadvantages or undesired Cre activities in other 
cell populations. For instance, Mcpt5-Cre mice enable gene 
inactivation only in connective tissue mast cells but not in 
mucosal mast cells, and Cre activity in this model has also 
been reported in a small fraction of NK cells in blood (Du-
deck et al., 2011). Similarly, although the Cpa3-Cre model 
enables gene inactivation in both mucosal mast cells and 
connective tissue mast cells, Cpa3 is also expressed by baso-
phils, some populations of T cell progenitors, thymic T cells, 
and hematopoietic progenitor cells. In line with this, “Hello 
Kitty” mice also have defects in non–mast cell populations 
and show macrocytic anemia (Lilla et al., 2011). Apart from 
these models, it has been shown that genetic deficiency of 
several genes could also result in impaired mast cell devel-
opment in mice (Table 1).
Finally, although mouse models have greatly contrib-
uted to our understanding of mouse mast cells, the contri-
bution of human mast cells to in vivo responses has been 
difficult to analyze. Therefore, a humanized mouse model 
(NSG-SGM3 BLT mice) has recently been developed (Bryce 
et al., 2016). This model provides a rich source of human mast 
cells that could be activated by chimeric IgE molecules and 
could be used to develop in vivo disease models in which 
therapeutics may be tested.
Mast cell–mediated human diseases
The involvement of mast cells in the progression of many 
human diseases is becoming increasingly clear, and many 
therapeutics are being developed to control abnormal mast 
cell activation and proliferation in several inflammatory dis-
eases, including allergic asthma, rhinitis, conjunctivitis, der-
matitis, food allergies, chronic rhinosinusitis, nasal polyps, 
aspirin-exacerbated respiratory disease (AERD), and chronic 
urticaria (Galli and Tsai, 2012). In these conditions, mast cells, 
together with other immune cells such as eosinophils, macro-
phages, and T cells, are involved in disease progression. These 
diseases affect both adults and children, and the prevalence of 
allergic diseases is estimated to be 19.6% of the population. 
In 2007, the financial cost of allergies was estimated to be $6 
billion USD (Beggs et al., 2015).
Primary mast cell dysfunction results in mastocytosis and 
mast cell activation disorders (MCADs; Ustun et al., 2016). 
Whereas mastocytosis involves the aberrant accumulation of 
mast cells in many tissues and organs, MCADs involve the 
chronic, uncontrolled activation of mast cells. Importantly, sev-
eral causative mutations have been identified in mastocytosis 
patients, KIT D816V being the most common. KIT D816V 
mutation leads to autoactivation of KIT receptor tyrosine ki-
nase, which then constitutively drives mast cell proliferation 
(Valent et al., 2017). Additional KIT mutations (such as KIT 
D419H and M541L) and mutations in other genes (such as 
c-CBL, TET2, SRSF2, ASXL1, and RUNX1) have also re-
cently been identified in mastocytosis patients (Schwaab et 
al., 2013; Jawhar et al., 2016). Although it is unknown if these 
mutations are drivers or passengers, their coexistence with 
common KIT mutations may lead to increased proliferation or 
hyperactivation of mast cells and is a marker for poor prognosis 
in mastocytosis patients (Jawhar et al., 2016). Therefore, it is 
important to determine which specific non-KIT mutations 
also predispose individuals to mastocytosis. Given the facts 
that epigenetic regulators DNMT3a and TET2 have been 
shown to modulate mast cell proliferation in mice (Montag-
ner et al., 2016; Leoni et al., 2017) and that DNMT3a and 
TET2 mutations are also frequent in human mastocytosis pa-
tients (Traina et al., 2012), it is also imperative to determine 
whether these mutations affect the expression or catalytic 
functions of TET2 and DNMT3a.
Table 1. Selected examples of genes important for mast cell development
Gene Mouse model Phenotype Reference
GATA2 GATA2ΔCF Loss of mast cell phenotype in BMMCs Ohmori et al., 2015
STAT5 STAT5A/B +/− Deficiency of mast cells in all analyzed tissues Shelburne et al., 2003
MITF MITF −/− (tg/tg mice) Deficiency of mast cells in peritoneum, mesentery, stomach, spleen Morii et al., 2004
NDST2 NDST2 −/− Decreased numbers of connective tissue mast cells and reduced mast cell 
proteases and histamine content
Forsberg et al., 1999
HDC HDC −/− mice Decreased numbers of peritoneal and mesenterial mast cells and decreased 
histamine content
Ohtsu et al., 2001
CPA3 CPA3 −/− mice Immature peritoneal mast cells with reduced granular staining Feyerabend et al., 2005
PI3K p85α −/− and p110γ −/− DKO mice Severe defects in mast cell development Takayama et al., 2013
PI3K p85α −/− mice Mast cell deficiency in gastrointestinal and peritoneal mast cells Fukao et al., 2002
AHR AHR −/− mice Reduction in skin, peritoneal cavity, and stomach mucosa–resident mast cells Zhou et al., 2013
SRGN SRGN −/− mice Deficiency in granulated mast cells in peritoneum and ear Åbrink et al., 2004
PLA2G3 PLA2G3 −/− mice Irregularly shaped and immature tissue mast cells Taketomi et al., 2013
Mac-1 (CD11b/CD18, CR3) Mac-1 −/− mice Decreased number of mast cells in peritoneum and dorsal epidermis Rosenkranz et al., 1998
P38α Mx-Cre+ P38αF/F (P38α−/−) Decreased numbers of peritoneal and lung mast cells Hu et al., 2012
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Figure 4. Clinical targeting of mast cell functions. There are various extracellular cytokines that are released from mast cells or that regulate the 
mast cell responses after binding to their corresponding receptors on mast cells. Some of these cytokines have been targeted using blocking monoclonal 
antibodies, which are in use to treat allergic disorders such as asthma. These cytokines include TNF, IL-1, IL-5, IL-9, IL-13, IL-17A, IL-33, GM-CSF, and thymic 
stromal lymphopoietin (TSLP). Furthermore, extracellular IgE is targeted with Omalizumab, and histamine is targeted with antihistamines. Similarly, many 
cell-surface receptors involved in mast cell activation are also therapeutic targets. These receptors include IL-4Rα (a common receptor for IL-4 and IL-13), 
cysteinyl leukotriene receptor 1 (CYS LTR1), and β-2 adrenergic receptor (ADRB2). Intracellular targets in mast cells include Syk kinase (mediating LAT phos-
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Apart from mast cell clonal diseases and activation 
disorders, some patients show abnormal levels of mast cell–
derived mediators in basal conditions. Because mast cell 
proteases are secreted upon mast cell activation, their abnor-
mal levels in blood serum is also a significant risk factor for 
developing inflammatory disorders. It has been shown that 
basal serum levels of tryptase are higher in some individu-
als without showing signs of mastocytosis (Fellinger et al., 
2014). Using genome sequencing to account for the genetic 
cause of elevated basal tryptase levels in a cohort of patients, 
germline duplications and triplications in TPS AB1 gene 
coding for α-tryptase protein have recently been identified 
(Lyons et al., 2016). These patients with higher basal tryptase 
levels show various clinical features, including joint hyper-
mobility, skeletal abnormalities, body pain, and headaches. 
Importantly, peripheral blood–derived mast cells generated 
from these patients exhibit more spontaneous tryptase secre-
tion (Lyons et al., 2016).
Novel approaches in clinical targeting of mast cell functions
The actions of mast cell–derived mediators contribute to the 
pathophysiology of common allergic disorders. In clinical set-
tings, various strategies targeting intracellular or extracellular 
mast cell mediators have traditionally been tested in allergic 
patients, and some of them are in common clinical use (Fig. 4). 
However, some of these treatments are only partially effective, 
have sedative side effects, are not tolerated by all patients, or 
are considered safe to use long term in children. For instance, 
corticosteroids (e.g., oral prednisolone, topical budesonide 
and fluticasone) suppress some of the IgE-mediated activities 
and provide partial to complete short-term symptom control. 
However, some patients are resistant to the effect of cortico-
steroids, whereas others develop corticosteroid resistance over 
the course of their disease (often those with severe asthma or 
nasal polyps; Aversa et al., 2012; Barnes, 2013). Furthermore, 
oral corticosteroids are not safe for all patients, especially those 
with peptic ulcer disease or a history of shingles, and their 
long-term use has numerous well-known side effects (Narum 
et al., 2014). Antihistamines also have variable efficacy and 
sedative side effects. Some newer therapies have been recently 
designed to improve the efficacy profile in patients (Akdis, 
2012). For example, Omalizumab is a humanized monoclo-
nal antibody that binds to free IgE in circulation, acting as a 
competitive inhibitor for binding to FcεR1 (Normansell et 
al., 2014). It is an FDA-approved drug currently in use to treat 
severe asthma and chronic idiopathic urticaria. Furthermore, 
anti–IL-5 monoclonal antibody (e.g., Mepolizumab) has also 
shown promising results in patients with severe asthma (Or-
tega et al., 2014). Similarly, newer biologics such as anti–IL-4/
anti–IL-13 monoclonal antibody (Dupilumab) are showing 
better efficacy profiles compared with corticosteroid alone 
in atopic dermatitis, chronic rhinosinusitis, and nasal polyps 
(Thaçi et al., 2016; Wenzel et al., 2016). This highlights the 
notion that multiple therapeutic targets are required to con-
trol chronic inflammation.
Targeting upstream molecules controlling the activa-
tion of numerous proinflammatory downstream mediators is 
an attractive therapeutic approach. For example, GATA-3 is 
a critical TF controlling the expression of Th2 genes, which is 
a common signature in asthma. Traditionally, TFs were con-
sidered to be difficult to target in vivo, but deoxyribozyme 
(DNAzyme) technology has promise in this field of ther-
apeutics. Notably, an inhaled GATA-3–specific DNAzyme, 
SB010, has been shown to be effective in cleaving and in-
activating GATA-3 mRNAs, in turn reducing mRNA and 
protein levels of GATA-3. More importantly, SB010 has 
demonstrated considerable efficacy in clinical trials with al-
lergic asthma patients (Krug et al., 2015). Similar approaches 
might also be beneficial to target upstream regulators of mast 
cell functions in other mast cell–related diseases, including 
mastocytosis and MCADs.
Use of antisense oligonucleotides is another promis-
ing approach for therapeutic targeting of mast cell functions. 
For example, MS4A2 loci coding for the β chain of FcεR1 
(FcεR1β) is associated with allergies in humans (Kim et al., 
2006) and, in a recent study, a truncated variant of FcεR1β 
(t-FcεR1β) was also identified in human mast cells (Cruse 
et al., 2010). T-FcεR1β lacks exon 3 of MS4A2, coding for 
the first two transmembrane domains of FcεR1β; therefore, 
t-FcεR1β does not traffic to the plasma membrane (Cruse 
et al., 2013). Antisense oligonucleotide–mediated exon skip-
ping has been successfully applied to specifically manipulate 
MS4A2 splicing, target FcεR1β, and down-regulate the ex-
pression and activation of FcεR1 (Cruse et al., 2016). Nota-
bly, local applications of antisense oligonucleotides have the 
potential to control mast cell responses in allergic disorders. 
Another promising therapeutic target for allergic diseases 
is the MRG PRX2 receptor. Because of its specific expres-
sion pattern on connective tissue mast cells (apart from some 
neurons), targeting MRG PRX2 receptor activation with 
small-molecule inhibitors or monoclonal antibodies might 
alleviate common pseudoallergic reactions.
Inhibitory receptors such as sialic acid binding Ig-like 
lectin (Siglec) receptors represent further novel therapeutic 
targets in mast cells. Although there are many Siglec recep-
tors with different expression patterns in immune cells, Siglec 
8 is specifically expressed in human mast cells and eosino-
phils, and pretreatment of human mast cells generated from 
phorylation and signal propagation), intracellular calcium, arachidonate 5–lipoxygenase (ALOX5; important for leukotriene synthesis), cyclooxygenase 2 
(COX-2; important for prostaglandin synthesis), calcineurin (phosphatase activating NFAT TF), and the glucocorticoid receptor (inhibiting proinflammatory 
cytokine synthesis). Inhibitory receptor Siglec 8 is also another therapeutic target. Promising future therapies might also include the use of antisense oligo-
nucleotides, DNAzymes, and small-molecule inhibitors of MRG PRX2 receptor activation.
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CD34+ precursors with an antibody activating Siglec 8 has 
been shown to inhibit mast cell degranulation (Kiwamoto et 
al., 2012). Importantly, clinical trials with antibodies activating 
Siglec 8 (AK001 and AK002) are ongoing in nasal polyposis 
and systemic mastocytosis patients. Similarly, Siglec 7 has also 
been shown to dampen FcεR1-dependent mast cell activa-
tion (Mizrahi et al., 2014), and antibodies activating Siglec 7 
could also be a viable therapeutic option in the future.
Concluding remarks and future directions
Mast cells play an increasingly recognized role in health and 
disease. Recent developments in mast cell research have rein-
forced the understanding that mast cells have unique immune 
functions, a deeper understanding of which will have a great 
impact on human health. As new genomic tools and mouse 
models become more available, our understanding of mast cell 
functions and plasticity will continue to increase. However, 
there are still several challenges to be addressed for better con-
trol of mast cell activation and proliferation in disease settings.
First of all, mouse and human mast cells may have func-
tional differences, and findings on mouse mast cells should be 
supported by studies on human mast cells wherever possible. 
In particular, we believe that humanized mouse models will 
be a valuable tool to investigate the functions of human mast 
cells in vivo. Second, with the recent advances in cutting-edge 
techniques such as CRI SPR, single-cell sequencing, and 
CyTOF, it is now feasible to identify novel molecular tar-
gets and delineate previously unknown genetic and epigene-
tic mechanisms in human mast cells. For instance, single-cell 
sequencing shows great promise in uncovering subpopula-
tions of various tissue-resident cells, and it could be applied 
to delineate specific subpopulations of mast cells in different 
human tissues in steady state as well as in acute and chronic 
inflammatory settings. Furthermore, we still have a very lim-
ited understanding of the roles of noncoding RNAs in mast 
cell development or activation. Many studies have shown that 
noncoding RNAs play an important role in controlling in-
flammatory responses, and it is conceivable that long non-
coding RNAs might also play a previously unknown role in 
mast cell development or activation. Loss-of-function studies 
using CRI SPR in human mast cells will help determine the 
unknown roles of RNAs in mast cell biology.
Because mast cells generate many different cytokines, 
chemokines, and other soluble mediators, targeting an up-
stream regulator rather than a single mediator will undoubt-
edly be a more viable approach in controlling allergic diseases. 
In this regard, further research on the MRG PRX2 receptor 
will provide important clues to control pseudoallergic reac-
tions commonly seen in the population.
Finally, it is now widely accepted that the microbiome 
has immense effects on human physiology and that many 
diseases have connections with tissue-specific microbiomes. 
Because mast cells also reside in the skin and intestines, the 
effects of the skin and gut microbiome on mast cell functions 
should be further investigated.
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